What did we learn in 2010 from the phase III trials? Is maintenance therapy the new standard for myeloma?

Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S30-2. doi: 10.1016/j.bbmt.2010.11.016.

Authors

Sergio Giralt¹, Edward Stadtmauer, Phillip McCarthy

Affiliation

¹ Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. sgiralt@mdanderson.org

PMID: 21195307
DOI: 10.1016/j.bbmt.2010.11.016

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / therapeutic use
Clinical Trials, Phase III as Topic / methods
Clinical Trials, Phase III as Topic / standards
Disease Progression
Hematopoietic Stem Cell Transplantation
Humans
Multiple Myeloma / therapy*
Treatment Outcome

Substances

Antineoplastic Agents